sjsa1  (ATCC)

Journal: bioRxiv

Article Title: In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma

doi: 10.64898/2026.02.19.706776

Figure Lengend Snippet: (A) 143B cells (osteosarcoma) show greater proliferation than hFOB cells (osteoblast control cells) in both high (25 mM) and low (5.6 mM) glucose media in three replicate experiments. (B) Mitochondrial membrane potential of 143B cells was significantly decreased when glucose media was changed from 25 mM to 5.6 mM comparing with hFOB cells in three biological replicate experiments.. (C) Mitochondrial membrane potential of the osteosarcoma cells was surprisingly greater in high glucose but lower in low glucose media. (D) Cell viability of 143B cells normalized to hFOB cells in 5.6 mM glucose or 10 mM galactose medium. Only the 143B osteosarcoma cells had significantly reduced viability in galactose media compared to both hFOB cells in galactose and 143B cells in glucose. (E) Cell viability of 6 osteosarcoma cell lines (including 5 primary tumor derived lines: HOS, MG-63, Saos-2, SJSA-1, U2 OS, and one pulmonary metastasis derived line: 15454-307) grown in 5.6 mM glucose or 10 mM galactose medium. Significant reductions of cell viability to variable degrees were seen in galactose conditions for all cell lines except HOS. Three biological replicate experiments per condition. All boxplots show the median of the data, the boxes mark the limits of the second and third quartiles and the whiskers the smallest and largest values no more than 1.5 times +/- the interquartile range. Points outside that range are considered “outlying” and are plotted individually. Differences between the groups were tested with ANOVA with a post-hoc Tukey test while controlling for biological replicates.

Article Snippet: Authenticated human osteosarcoma cell lines were obtained: 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), HOS (ATCC Cat# CRL-1543, RRID:CVCL_0312), MG-63 (ATCC Cat# CRL-1427, RRID:CVCL_0426), Saos-2 (ATCC Cat# HTB-85, RRID:CVCL_0548), SJSA-1 (ATCC Cat# CRL-2098, RRID:CVCL_1697), U-2 OS (ATCC Cat# HTB-96, RRID:CVCL_0042) and osteoblast cell lines hFOB 1.19 ((ATCC Cat# CRL-3602, RRID:CVCL_3708), hFOB) and NHOst (Lonza Cat #: CC-2538).

Techniques: Control, Membrane, Derivative Assay

Journal: European Journal of Medical Research

Article Title: Deciphering stromal cell interactions in osteosarcoma highlights CDKN2A and MMP14 as novel diagnostic and therapeutic biomarkers

doi: 10.1186/s40001-026-03902-2

Figure Lengend Snippet: Regulatory role of biomarker MMP14 in the malignant phenotype of Osteosarcoma cell lines. A Expression of MMP14 and CDKN2A in cell lines U-2OS and SJSA-1 compared to hFOB1.19. B Construction of MMP14-silenced U-2OS and SJSA-1 cell lines. C CCK-8 assay measuring cell proliferation in U-2OS/si-MMP14 and SJSA-1/si-MMP14 cells. D Transwell assay assessing relative invasion levels in U-2OS/si-MMP14 and SJSA-1/si-MMP14 cells. E Scratch healing assay for relative migration levels in U-2OS/si-MMP14 and SJSA-1/si-MMP14. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Article Snippet: hFOB1.19, U-2 OS, and SJSA-1 cell lines were purchased from ATCC (USA).

Techniques: Biomarker Discovery, Expressing, CCK-8 Assay, Transwell Assay, Migration